Skip to Content

Ixense

Active Substance: apomorphine hydrochloride
Common Name: apomorphine
ATC Code: G04BE
Marketing Authorisation Holder: Takeda Europe R&D Centre Ltd.
Active Substance: apomorphine hydrochloride
Status: Withdrawn
Authorisation Date: 2001-05-28
Therapeutic Area: Erectile Dysfunction
Pharmacotherapeutic Group: Urologicals

Therapeutic Indication

Treatment of men with erectile dysfunction, which is the inability to achieve or maintain a penile erection sufficient for satisfactory sexual performance.
In order for Ixense to be effective, sexual stimulation is required.

The marketing authorisation for Ixense has been withdrawn at the request of the marketing authorisation holder.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Hide